Revenue and Operating Profit Targets for the Fiscal Year Ending March 2026
First written in FY2023-Q3. 3 of 6 entries say "Softened", first in FY2025. Latest entry: FY2026.
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
- FY2026Shortfall against the medium-term management plan's numerical targets confirmedAnnual report
「As a result, the numerical targets of ¥40 billion in net sales and ¥7 billion in operating profit were not achieved, largely because we were unable during the period to obtain U.S. approval for and launch SI-6603, a treatment for lumbar disc herniation.」
The company concluded that the FY2026 targets of ¥40.0 billion in revenue and ¥7.0 billion in operating profit could not be achieved during the medium-term management plan period, due to the failure to obtain U.S. approval for and launch SI-6603. - FY2025SoftenedAnnual report
「Going forward, we aim to resubmit SI-6603 within 1 year of receiving this notice. However, commercialization during the medium-term management plan period will be difficult, making it difficult to achieve the numerical targets of ¥40 billion in net sales and ¥7 billion in operating profit.」
The view changed to one that the FY2026 targets of ¥40.0 billion in revenue and ¥7.0 billion in operating profit would be difficult to achieve due to the deteriorating outlook for the U.S. launch of SI-6603. - FY2024AdvancedAnnual report
「The numerical targets for FY2026, the final year of the medium-term management plan covering FY2023 to FY2026, are as follows. FY2022 results FY2026 targets Revenue ¥34.8 billion ¥40.0 billion Operating profit ¥4.4 billion ¥7.0 billion <Assumptions> ① U.S. launch of SI-6603, a treatment for lumbar disc herniation ② Revenue growth from domestic joint-function improvement treatments ③ Expansion of the overseas pharmaceutical and LAL businesses ④ R&D expenses targeted at 25% of revenue, excluding royalties ⑤ Exchange rate: ¥135 to the U.S. dollar In FY2024, progress on each priority initiative was generally in line with plan.」
The company reiterated its FY2026 targets of ¥40.0 billion in revenue and ¥7.0 billion in operating profit, together with the assumptions, and reported that progress on its priority initiatives in FY2024 was generally in line with plan. - FY2023-Q3First statedAnnual report
「The numerical targets for FY2026, the final year of the medium-term management plan covering FY2023 to FY2026, are as follows. FY2022 results FY2026 targets Revenue ¥34.8 billion ¥40.0 billion Operating profit ¥4.4 billion ¥7.0 billion」
Targets of ¥40.0 billion in revenue and ¥7.0 billion in operating profit were set for FY2026. The assumptions included the U.S. launch of SI-6603, revenue growth from domestic joint-function improvement treatments, expansion of the overseas pharmaceutical and LAL businesses, an R&D expense ratio of approximately 25%, and an exchange rate of ¥135 to the U.S. dollar.